Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Summary Background New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2009-08, Vol.374 (9688), p.459-466
Hauptverfasser:	van Vollenhoven, RF, Dr, Ernestam, S, MD, Geborek, P, MD, Petersson, IF, MD, Cöster, L, MD, Waltbrand, E, MD, Zickert, A, MD, Theander, J, MD, Thörner, Å, MD, Hellström, H, MD, Teleman, A, MD, Dackhammar, C, MD, Akre, F, MD, Forslind, K, MD, Ljung, L, MD, Oding, R, MD, Chatzidionysiou, A, MD, Wörnert, M, RN, Bratt, J, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies, Monoclonal - therapeutic use Antiparasitic agents Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Autoimmune diseases Biological and medical sciences Clinical Medicine Clinical trials Data analysis Diseases of the osteoarticular system Drug therapy Female General aspects Humans Hydroxychloroquine - therapeutic use Inflammatory joint diseases Infliximab Internal Medicine Klinisk medicin Male Medical and Health Sciences Medical sciences MEDICIN Medicin och hälsovetenskap MEDICINE Methotrexate - therapeutic use Middle Aged Orthopedics Ortopedi Patients Pharmacology. Drug treatments Quality control Recruitment Reumatologi och inflammation Rheumatoid arthritis Rheumatology Rheumatology and Autoimmunity Studies Sulfasalazine - therapeutic use Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate in patients with early rheumatoid arthritis. Methods We undertook a randomised trial in 15 rheumatology units in Sweden. We enrolled patients with early rheumatoid arthritis (symptom duration
ISSN:	0140-6736 1474-547X 1474-547X
DOI:	10.1016/S0140-6736(09)60944-2